AstraZeneca Plc (NASDAQ: AZN) $78.26 (0.3%) $0.24 Price as of October 18, 2024, 4:00 p.m. ETAstraZeneca Plc Return vs. S&P 1 Year5 Year5 Year AnnualizedSince IPO AZN +24.11% +101.34% +15.01% +4,205% S&P +37.09% +96.39% +14.44% +1,218% AstraZeneca Plc Company Info ...
ASTRAZENECA End of interactive chart. Price information What's this? Open price 10,520.00 Previous close price / date 10,524.00 / 17 December 2024 Volume 1,359,168 Turnover (on book) £129,864,995.58 52 week range 9,443.00 / 13,388.00 ...
View AstraZeneca (AZN) stock price, news, historical charts, analyst ratings, financial information and quotes on Futubull. Trade commission-free with the Futubull stock trading app.
U.K. stocks fall for first time in five days Dec. 4, 2024 at 12:05 p.m. ETby MarketWatch Automation AstraZeneca rises Tuesday, outperforms market Dec. 3, 2024 at 12:02 p.m. ETby MarketWatch Automation AstraZeneca falls Monday, underperforms market ...
AstraZeneca PLC (ZEG) has a Smart Score of 10 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.
fueling future growth allka research tue, jun. 25 5 comments astrazeneca: the price upside is exhausted for now (rating downgrade) manika premsingh sat, jun. 15 7 comments astrazeneca: plotting a bold path to $80 billion revenues, i'm pausing for breath edmund ingham fri, may 24 4 ...
Stock futures slip lower as Covid worries and inflation concerns come into focus; AstraZeneca gets FDA nod for its antibody treatment; Jefferies sends bankers home after NY Covid outbreak; Amazon hit with record $1.3 billion fine in Italy and GameStop unveils a wider third quarter loss and de...
Q&A For AstraZeneca PLC Stock AstraZeneca PLC stock price133.93 USD Previous Close146.88 USD Open148.3 USD Bid0 USD x 0 Ask0 USD x 0 Day's Range148.3 - 149.25 USD 52 Week Range104.5 - 153.1 USD Volume2.97K USD Avg. Volume4.8K USD ...
See AstraZeneca's detailed income statement and balance sheet. Find out their revenue, expenses and profit or loss over the last fiscal year.
AstraZeneca's Imfinzi Secures US FDA's Priority Review Tag for Bladder CancerDec. 06MT EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectationsDec. 05AN Stocks mixed, French political drama continuesDec. 05AN AstraZeneca Says Imfinzi Approved in US for Limited-Stage Small Cell Lu...